Free Trial
NASDAQ:KROS

Keros Therapeutics Q1 2024 Earnings Report

Keros Therapeutics logo
$15.56 -0.48 (-2.99%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$15.89 +0.33 (+2.15%)
As of 09/19/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Keros Therapeutics EPS Results

Actual EPS
-$1.21
Consensus EPS
-$1.33
Beat/Miss
Beat by +$0.12
One Year Ago EPS
-$1.26

Keros Therapeutics Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
-97.30%

Keros Therapeutics Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Keros Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Keros Therapeutics Earnings Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Keros Therapeutics Headlines

About Keros Therapeutics

Keros Therapeutics (NASDAQ:KROS) (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders.

Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.

View Keros Therapeutics Profile

More Earnings Resources from MarketBeat